Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309672 · ClinicalTrials.gov registry record · Phase 2
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01309672 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 41 participants.
The verdict
NCT01309672, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.
Interventions
- DRUG Prednisone
- DRUG abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-08-09 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01309672
The ClinicalTrials.gov registry entry for NCT01309672 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT01309672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01309672 about?
NCT01309672 is a clinical study titled "S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy". RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial i...
What is the current status of trial NCT01309672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-08-09. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT01309672?
The interventions under investigation include: Prednisone (DRUG), abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT01309672?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.